Bortezomib’s efficacy for solid tumors is inadequate due to resistance to cell death induction (30); nevertheless, insertion of arginylated calreticulin into the plasma membrane of glioma cells treated with bortezomib can initiate the apoptotic pathway (63). This evidence concerns the gene CALR and glioma.